Bikbov, Mukharram M.,
Kazakbaeva, Gyulli M.,
Panda-Jonas, Songhomitra,
Lakupova, Ellina M.,
Fakhretdinova, Albina A.,
Tuliakova, Azaliia M.,
Jonas, Jost B. (2024) -to-severe vision impairment (MSVI) in 202 eyes (44.6%; 95% CI: 40.0–49.2) and to
blindness in 53 eyes (11.7%; 95
Akhmadeeva, L.,
Valeeva, D.,
Naprienko, M.,
Goldobina, L.,
Rayanova, G.,
Veytsman, B. (2014) TENS) is one of them. We designed a protocol for a randomized double
blind placebo controlled clinical trial
coronarophraphy in patients with CKD stage I-II.
Methods: In randomized, sham-controlled
blind study 51 patient